Amneal Acquires India’s Puniska To Double Injectables Business
As Company Looks To Enter US Biosimilars Market In 2022
Amneal has acquired India’s Puniska Pharmaceticals in a deal worth $93m, with an aim to “more than double” its injectables business by 2025. Meanwhile, in the third quarter the company has reported growth in its generics and specialty segments, with Amneal looking to enter the biosimilars market next year.
